• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

European Commission Supports Indefinite Exemption Of LDCs From IPRs On Pharmaceuticals

10/09/2015 by Intellectual Property Watch 4 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Catherine Saez

In a communication today, the European Commission said it agrees to support a least developed country request at the World Trade Organization to prolong indefinitely a current exemption on the enforcement of IP on pharmaceutical products. Now the decision moves to the EU member states.

“This exemption allows generic medicines to be imported, and produced locally, regardless of patents, for example when licenses are not available,” the Commission said in a press release. “It means producers of generics and international programmes can supply drugs like HIV treatment in affected countries without fear of patent infringement suits.”

Least-developed countries (LDCs) have requested that the WTO Council for Trade-Related Intellectual Property Rights (TRIPS) prolong without end an exception that exonerates them from enforcing IP rights on pharmaceutical products. The exception has been extended before and is set to end at the close of year.

LDCs have asked that this extension be indefinite. Another exemption on all products runs alongside the pharmaceutical products exemption until 2021.

According to the release, Commissioner Malmström said although patents stimulate innovation in developed and emerging countries, IP rules should “be a non-issue when the world’s poorest are in need of treatment.”

The exemption “will give the least developed countries the necessary legal certainty to procure or to produce generic medicines.”

This decision now has to be confirmed by the European Council. This will determine the position of the EU at the next TRIPS Council meeting in October, the release said.

Médecins Sans Frontières Director of Policy for the Access Campaign Rohit Malpani said the health advocacy organisation welcomes the announcement by the Commission. “We hope that the EU Member States in the Council swiftly follow suit.”

“We applaud this important change in the EU position since the last time this issue was discussed at the WTO,” he said, urging the United States and Switzerland to also support the LDC request.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"European Commission Supports Indefinite Exemption Of LDCs From IPRs On Pharmaceuticals" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Development, English, Health & IP, Human Rights, Patents/Designs/Trade Secrets, WTO/TRIPS

Trackbacks

  1. Health Advocates Press United States On WTO LDC IP Waiver says:
    18/09/2015 at 2:04 pm

    […] Furthermore, the US should not attempt to “impose conditions that require LDCs to maintain existing degrees of IP protection,” the letter said, adding that the US “should join the emerging global consensus, supported even by the European Commission.” The Commission announced its support for the extension last week (IPW, EU Policy, 10 September 2015). […]

    Reply
  2. WTO TRIPS Council To Decide On LDC Pharma Extension, Non-Violation Complaints says:
    13/10/2015 at 8:47 am

    […] of organisations have called for the extension to be granted, as well as the European Commission (IPW, WTO/TRIPS, 10 September 2015). The decision had to be confirmed by the European […]

    Reply
  3. European Council Backs LDC Extension At WTO says:
    13/10/2015 at 6:24 pm

    […] saying it agrees to support the LDC request at the WTO as long as a country has LDC status (IPW, WTO/TRIPS, 10 September 2015). The decision then went to the European Council of ministers, which gave its […]

    Reply
  4. WTO TRIPS Council To Decide On LDC Pharma Extension, Non-Violation Complaints » infojustice says:
    15/10/2015 at 5:57 pm

    […] of organisations have called for the extension to be granted, as well as the European Commission (IPW, WTO/TRIPS, 10 September 2015). The decision has been confirmed by the European Council. […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.